Pharmacodynamic-Pharmacokinetic Integration as a Guide to Medicinal Chemistry

被引:24
|
作者
Gabrielsson, Johan [1 ,5 ]
Fjellstrom, Ola [2 ]
Ulander, Johan [2 ]
Rowley, Michael [3 ]
Van der Graaf, Piet H. [4 ]
机构
[1] AstraZeneca R&D, Discovery DMPK, S-43183 Molndal, Sweden
[2] AstraZeneca R&D, Lead Generat, S-43183 Molndal, Sweden
[3] AstraZeneca R&D, Med Chem, S-43183 Molndal, Sweden
[4] Pfizer Ltd, Sandwich Res Unit, Dept Pharmacokinet Dynam & Metab PDM & Global Pha, Sandwich CT13 9NJ, Kent, England
[5] AstraZeneca R&D, BAC, S-43183 Molndal, Sweden
关键词
Mechanism-based PKPD modelling; potency; efficacy; lipophilicity; structure-activity relationship; turnover models; effect compartment models; occupancy binding models; PLASMA-PROTEIN BINDING; PHARMACOLOGY; RATS; MODEL; TIME;
D O I
10.2174/156802611794480864
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A primary objective of pharmacokinetic-pharmacodynamic (PKPD) reasoning is to identify key in vivo drug and system properties, enabling prediction of the magnitude and time course of drug responses under physiological and pathological conditions in animals and man. Since the pharmacological response generated by a drug is highly dependent on the actual system used to study its action, knowledge about its potency and efficacy at a given concentration or dose is insufficient to obtain a proper understanding of its pharmacodynamic profile. Hence, the output of PKPD activities extends beyond the provision of quantitative measures (models) of results, to the design of future protocols. Furthermore, because PKPD integrates DMPK (e. g. clearance) and pharmacology (e. g. potency), it provides an anchor point for compound selection, and, as such, should be viewed as an important weapon in medicinal chemistry. Here we outline key PK concepts relevant to PD, and then consider real-life experiments to illustrate the importance to the medicinal chemist of data obtained by PKPD. Useful assumptions and potential pitfalls are described, providing a holistic view of the plethora of determinants behind in vitro-in vivo correlations. By condensing complexity to simplicity, there are not only consequences for experimental design, and for the ranking and design of compounds, but it is also possible to make important predictions such as the impact of changes in drug potency and kinetics. In short, by using quantitative methods to tease apart pharmacodynamic complexities such as temporal differences and changes in plasma protein binding, it is possible to target the changes necessary for improving a compound's profile.
引用
收藏
页码:404 / 418
页数:15
相关论文
共 50 条
  • [21] The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development
    Yu, Xiang-Qing
    Wilson, Alan G. E.
    FUTURE MEDICINAL CHEMISTRY, 2010, 2 (06) : 923 - 928
  • [22] Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma
    Matera, Maria Gabriella
    Rogliani, Paola
    Calzetta, Luigino
    Cazzola, Mario
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (02) : 239 - 245
  • [23] A pharmacokinetic and pharmacodynamic analysis of drug forgiveness
    McAllister, Noel P.
    Lawley, Sean D.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2022, 49 (03) : 363 - 379
  • [24] Pharmacokinetic-pharmacodynamic modelling in anaesthesia
    Gambus, Pedro L.
    Troconiz, Inaki F.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (01) : 72 - 84
  • [25] Pharmacodynamic and pharmacokinetic bases of mastitis therapy
    Kietzmann, M.
    Baeumer, W.
    JOURNAL FUR VERBRAUCHERSCHUTZ UND LEBENSMITTELSICHERHEIT-JOURNAL OF CONSUMER PROTECTION AND FOOD SAFETY, 2008, 3 (04): : 411 - 416
  • [26] Clinical Pharmacokinetic and Pharmacodynamic Profile of Lacosamide
    Cawello, Willi
    CLINICAL PHARMACOKINETICS, 2015, 54 (09) : 901 - 914
  • [27] Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
    Al-Shaer, Mohammad H.
    Alghamdi, Wael A.
    Alsultan, Abdullah
    An, Guohua
    Ahmed, Shahriar
    Alkabab, Yosra
    Banu, Sayera
    Barbakadze, Ketevan
    Houpt, Eric
    Kipiani, Maia
    Mikiashvili, Lali
    Cegielski, J. Peter
    Kempker, Russell R.
    Heysell, Scott K.
    Peloquin, Charles A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (07)
  • [28] PHARMACOKINETIC, PHARMACODYNAMIC, AND TOXICOLOGY STUDY OF ROBENACOXIB IN RAINBOW TROUT (ONCORHYNCHUS MYKISS)
    Raulic, Juliette
    Beaudry, Francis
    Beauchamp, Guy
    Jalenques, Marion
    Summa, Noemie
    Lair, Stephane
    Youcef, Wahiba Ait
    Vergneau-Grosset, Claire
    JOURNAL OF ZOO AND WILDLIFE MEDICINE, 2021, 52 (02) : 529 - 537
  • [29] Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone
    Thygesen, Peter
    Andersen, Henrik Sune
    Behrens, Carsten
    Fels, Johannes Josef
    Norskov-Lauritsen, Leif
    Rischel, Christian
    Johansen, Nils Langeland
    GROWTH HORMONE & IGF RESEARCH, 2017, 35 : 8 - 16
  • [30] Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
    Schachter, M
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2005, 19 (01) : 117 - 125